Literature DB >> 1737937

Analysis of the AP-1 sites in the IL-2 promoter.

J Jain1, V E Valge-Archer, A Rao.   

Abstract

We have investigated the role of the two AP-1 sites, located at approximately -150 and -180 bp relative to the transcription start site, in induction of the IL-2 promoter through the TCR/CD3 complex. We show that only the proximal (-150 bp) AP-1 site is functional in vitro, as judged by its ability to bind nuclear proteins from T cells stimulated with Ag or anti-CD3 epsilon. The inducible nuclear proteins binding to this site have the characteristics of AP-1, as judged by their kinetics of induction, the ability to compete and be competed efficiently by a metallothionein AP-1 site oligonucleotide, and their reaction with antibodies to Fos and Jun proteins. Mutations in the proximal AP-1 site greatly diminish or abrogate induction of the IL-2 promoter, indicating that the site is also functional in vivo. Although the distal (-180 bp) AP-1 site is incapable of direct binding to nuclear proteins from activated T cells, a mutation in this site diminishes IL-2 promoter induction, suggesting that this site may also be functional in vivo. Cotransfection of a 5' IL-2-chloramphenicol acetyltransferase plasmid with c-Fos and/or c-Jun enhances the induction of IL-2-chloramphenicol acetyltransferase activity, confirming that the IL-2 promoter contains a functional AP-1 site. Both AP-1 sites may be targets for c-Fos action, as inferred from the results of experiments in which c-Fos was cotransfected with internal deletion mutants of the IL-2 promoter lacking either AP-1 site. Northern analysis indicates that mRNAs for at least six members of the Fos/Jun family (c-fos, fosB, fra-1, c-jun, junB, and junD) are expressed in activated Ar-5 cells; thus the AP-1 sites of the IL-2 promoter may bind different dimeric Fos/Jun complexes at different times after T cell activation, perhaps mediating both positive and negative regulation of the IL-2 promoter.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737937

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Activation changes the spectrum but not the diversity of genes expressed by T cells.

Authors:  T K Teague; D Hildeman; R M Kedl; T Mitchell; W Rees; B C Schaefer; J Bender; J Kappler; P Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  IL-2 and IL-4 stimulate MEK1 expression and contribute to T cell resistance against suppression by TGF-beta and IL-10 in asthma.

Authors:  Qiaoling Liang; Lei Guo; Shaila Gogate; Zunayet Karim; Arezoo Hanifi; Donald Y Leung; Magdalena M Gorska; Rafeul Alam
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

3.  The tumour associated cell surface antigen A6H is costimulatory for human CD4+ but not CD8+ T cells.

Authors:  T Labuda; E Parra; G Hedlund; T Kalland; M Dohlsten
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

4.  Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes.

Authors:  G Baier-Bitterlich; F Uberall; B Bauer; F Fresser; H Wachter; H Grunicke; G Utermann; A Altman; G Baier
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

5.  A novel intronic cAMP response element modulator (CREM) promoter is regulated by activator protein-1 (AP-1) and accounts for altered activation-induced CREM expression in T cells from patients with systemic lupus erythematosus.

Authors:  Thomas Rauen; Konrad Benedyk; Yuang-Taung Juang; Claus Kerkhoff; Vasileios C Kyttaris; Johannes Roth; George C Tsokos; Klaus Tenbrock
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

6.  Activation of c-Jun N-terminal kinase (JNK) signalling in experimentally induced gastric lesions in rats.

Authors:  K Mitsuyama; O Tsuruta; Y Matsui; K Harada; N Tomiyasu; A Suzuki; K Takaki; J Masuda; K Handa; Y Satoh; B L Bennett; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

7.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.

Authors:  B L Bennett; D T Sasaki; B W Murray; E C O'Leary; S T Sakata; W Xu; J C Leisten; A Motiwala; S Pierce; Y Satoh; S S Bhagwat; A M Manning; D W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

8.  Insights into pathophysiology of dystropy through the analysis of gene networks: an example of bronchial asthma and tuberculosis.

Authors:  Elena Yu Bragina; Evgeny S Tiys; Maxim B Freidin; Lada A Koneva; Pavel S Demenkov; Vladimir A Ivanisenko; Nikolay A Kolchanov; Valery P Puzyrev
Journal:  Immunogenetics       Date:  2014-06-24       Impact factor: 2.846

9.  The cyclic AMP response element modulator {alpha} suppresses CD86 expression and APC function.

Authors:  Martina Ahlmann; Georg Varga; Karsten Sturm; Ralph Lippe; Konrad Benedyk; Dorothee Viemann; Thomas Scholzen; Jan Ehrchen; Frank U Müller; Matthias Seidl; Marek Matus; George C Tsokos; Johannes Roth; Klaus Tenbrock
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  Requirement for the basic helix-loop-helix transcription factor Dec2 in initial TH2 lineage commitment.

Authors:  Xuexian O Yang; Pornpimon Angkasekwinai; Jinfang Zhu; Juan Peng; Zhiduo Liu; Roza Nurieva; Xikui Liu; Yeonseok Chung; Seon Hee Chang; Bing Sun; Chen Dong
Journal:  Nat Immunol       Date:  2009-11-01       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.